DE602005019167D1 - Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung - Google Patents

Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung

Info

Publication number
DE602005019167D1
DE602005019167D1 DE602005019167T DE602005019167T DE602005019167D1 DE 602005019167 D1 DE602005019167 D1 DE 602005019167D1 DE 602005019167 T DE602005019167 T DE 602005019167T DE 602005019167 T DE602005019167 T DE 602005019167T DE 602005019167 D1 DE602005019167 D1 DE 602005019167D1
Authority
DE
Germany
Prior art keywords
angiopoietin
protein
combinations
hemmer
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005019167T
Other languages
German (de)
English (en)
Inventor
Napoleone Ferrara
Hans-Peter Gerber
Xiao Huan Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35787710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005019167(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE602005019167D1 publication Critical patent/DE602005019167D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
DE602005019167T 2004-07-20 2005-07-19 Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung Expired - Lifetime DE602005019167D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58978204P 2004-07-20 2004-07-20
PCT/US2005/025734 WO2006014729A2 (en) 2004-07-20 2005-07-19 Inhibitors of angiopoietin-like 4 protein, combinations, and their use

Publications (1)

Publication Number Publication Date
DE602005019167D1 true DE602005019167D1 (de) 2010-03-18

Family

ID=35787710

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005019167T Expired - Lifetime DE602005019167D1 (de) 2004-07-20 2005-07-19 Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung

Country Status (23)

Country Link
US (2) US7740846B2 (enExample)
EP (3) EP2361931B1 (enExample)
JP (2) JP4947717B2 (enExample)
KR (1) KR101254815B1 (enExample)
CN (2) CN102641503A (enExample)
AT (1) ATE456579T1 (enExample)
AU (2) AU2005269716B2 (enExample)
BR (1) BRPI0513534A (enExample)
CA (1) CA2574758A1 (enExample)
CY (1) CY1109931T1 (enExample)
DE (1) DE602005019167D1 (enExample)
DK (1) DK1771474T3 (enExample)
ES (1) ES2339789T3 (enExample)
IL (1) IL180725A0 (enExample)
MX (1) MX2007000784A (enExample)
NO (1) NO20070951L (enExample)
NZ (1) NZ552956A (enExample)
PL (1) PL1771474T3 (enExample)
PT (1) PT1771474E (enExample)
RU (1) RU2392966C2 (enExample)
SI (1) SI1771474T1 (enExample)
WO (1) WO2006014729A2 (enExample)
ZA (1) ZA200701183B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7883720B2 (en) 2003-07-09 2011-02-08 Wisconsin Alumni Research Foundation Charge-dynamic polymers and delivery of anionic compounds
ATE456579T1 (de) 2004-07-20 2010-02-15 Genentech Inc Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
NZ552957A (en) 2004-07-20 2011-06-30 Genentech Inc Compositions and methods of using angiopoietin-like 4 protein
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
CA2594233C (en) 2005-01-07 2015-02-24 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 )
US8734851B2 (en) * 2005-04-29 2014-05-27 Wisconsin Alumni Research Foundation Localized delivery of nucleic acid by polyelectrolyte assemblies
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
KR100962301B1 (ko) * 2006-11-03 2010-06-11 재단법인서울대학교산학협력재단 자궁경부암을 위한 치료용 조성물
KR20150097813A (ko) * 2006-12-19 2015-08-26 제넨테크, 인크. 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 ｖｅｇｆ－특이적 길항제
US8834918B2 (en) * 2007-01-22 2014-09-16 Wisconsin Alumni Research Foundation Modified multilayered film
EP2178531A4 (en) * 2007-07-02 2012-01-11 Yu Ming METHODS AND COMPOSITIONS, TARGETS FOR COMBINED CANCER TREATMENTS
US20090105375A1 (en) * 2007-10-09 2009-04-23 Lynn David M Ultrathin Multilayered Films for Controlled Release of Anionic Reagents
US8126437B1 (en) 2008-01-24 2012-02-28 Invent Again Ubiquitous voice messaging
US8324333B2 (en) 2008-06-05 2012-12-04 Wisconsin Alumni Research Foundation Anionic charge-dynamic polymers for release of cationic agents
ES2890230T3 (es) * 2008-07-16 2022-01-18 Baylor Res Institute Vacuna contra el VIH basada en el direccionamiento de Gag y Nef maximizado a células dendríticas
PL2361085T5 (pl) 2008-11-22 2018-12-31 F.Hoffmann-La Roche Ag Zastosowanie przeciwciała anty-vegf w połączeniu z chemioterapią w leczeniu raka sutka
CA2748765C (en) 2009-07-06 2014-07-22 Akebia Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
EP2488640B1 (en) * 2009-10-14 2018-09-26 Nanyang Technological University Antiproliferative agent
CN111700901A (zh) 2010-01-08 2020-09-25 Ionis制药公司 血管生成素样3表达的调节
US9139629B2 (en) * 2010-06-05 2015-09-22 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
US9475850B2 (en) 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
EP3311835B1 (en) * 2010-07-12 2021-03-24 Threshold Pharmaceuticals Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
WO2012088254A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
KR102164964B1 (ko) * 2011-07-22 2020-10-14 페이실렉스 파마슈티컬스 인코포레이티드 암의 합성치사 및 치료
WO2013022406A1 (en) * 2011-08-08 2013-02-14 Nanyang Technological University Angiopoietin-like 4 and its use in modulating cell leakiness
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
US20150210758A1 (en) * 2012-08-14 2015-07-30 Nanyang Technological University Angiopoietin-like 4 antibody and a method of its use in cancer treatment
US9259435B2 (en) 2012-08-31 2016-02-16 W. L. Gore & Associates, Inc. Reactive oxidative species generating materials and methods of use
CN110974967B (zh) * 2012-10-30 2023-11-07 厄尔莱克斯制药公司 合成致死与癌症的治疗
KR101407730B1 (ko) * 2012-11-23 2014-06-12 인하대학교 산학협력단 안지오포이에틴-4 단백질을 유효성분으로 포함하는 발기부전의 예방 또는 치료용 조성물
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
KR102298476B1 (ko) 2013-12-24 2021-09-03 아이오니스 파마수티컬즈, 인코포레이티드 안지오포이에틴-유사 3 발현의 조절
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
EP3137605B1 (en) * 2014-05-01 2020-10-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
DK3177642T3 (da) * 2014-08-07 2022-02-21 Novartis Ag Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
US11788145B2 (en) 2015-07-17 2023-10-17 Pacylex Pharmaceuticals Inc. Epigeneiic silencing of NMT2
MX387804B (es) 2015-09-23 2025-03-19 Aerpio Therapeutics Inc Metodos para tratar presion intraocular con activadores de tie-2
CN106596979B (zh) * 2017-02-28 2018-10-09 汉氏联合（天津）干细胞研究院有限公司 一种用于帕金森综合症检测的试剂盒及其检测方法
MX2021005507A (es) * 2018-11-13 2021-06-18 Lipigon Pharmaceuticals Ab Oligonucleotidos de angptl4 que influyen en la regulacion del metabolismo de los acidos grasos.
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
CN119607006A (zh) * 2019-12-09 2025-03-14 艾姆皮瑞克公司 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
CN112611877B (zh) * 2020-12-31 2022-09-16 四川大学华西医院 一款利用angptl4预测急性呼吸窘迫综合征患病及预后的试剂盒
CN113797355B (zh) * 2021-10-14 2023-07-21 四川大学华西医院 具有滑膜炎症抑制功能的纳米材料的制备方法及应用
WO2025040097A1 (zh) * 2023-08-22 2025-02-27 成都先衍生物技术有限公司 一种靶向ANGPTL4的siRNA及其缀合物和用途
CN119405811A (zh) * 2024-11-13 2025-02-11 杭州师范大学 禁食诱导因子Angptl4蛋白作为分子靶点在治疗或预防压力性脱发中的应用

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) * 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
JPH08500962A (ja) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ，インコーポレイテッド 癌マーカー用生物合成結合蛋白質
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
RU2170589C2 (ru) * 1992-10-28 2001-07-20 Генентек Инк. Композиция для ингибирования ангиогенеза, моноклональное антитело, полипептид, способ ингибирования роста опухоли (варианты)
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DK1325932T5 (da) * 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
PT1695985E (pt) 1997-04-07 2011-06-06 Genentech Inc Métodos para formar anticorpos humanizados por mutagénese aleatória
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US20030207375A1 (en) 1997-10-24 2003-11-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1931599A (en) 1997-12-19 1999-07-12 Zymogenetics Inc. Angiopoietin homolog, dna encoding it, and method of making it
AU3065799A (en) 1998-03-02 1999-09-20 Dana-Farber Cancer Institute, Inc. Novel fdrg protein and nucleic acid molecules and uses therefor
AU4682999A (en) * 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
WO1999067382A2 (en) 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
DE59914547D1 (de) 1998-07-15 2007-12-20 Max Planck Gesellschaft Polyelektrolythüllen auf biologischen templaten
US6375447B1 (en) 1998-09-29 2002-04-23 Cq Inc. Apparatus for dewatering and pelletizing particulate fuel
WO2001054477A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001057188A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001053455A2 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2000308488A (ja) 1999-02-23 2000-11-07 Herikkusu Kenkyusho:Kk 血管新生に関連するタンパク質および該タンパク質をコードする遺伝子
WO2000052165A2 (en) 1999-03-04 2000-09-08 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
WO2000061629A1 (en) 1999-04-09 2000-10-19 Human Genome Sciences, Inc. 49 human secreted proteins
ATE420177T1 (de) 1999-04-16 2009-01-15 Genentech Inc Vaskuläre endothelzellen wachstumsfaktor (vegf) varianten und dessen verwendungen
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2001002429A2 (en) 1999-07-02 2001-01-11 Bayer Aktiengesellschaft Angiopoietin-6 and uses thereof
EP1210363A2 (en) 1999-07-16 2002-06-05 Hyseq, Inc. Novel angiopoietin materials and methods
US20030207348A1 (en) * 1999-07-20 2003-11-06 Shimkets Richard A. Polypeptides and polynucleotides encoding same
WO2001005971A2 (en) 1999-07-20 2001-01-25 Curagen Corporation Secreted polypeptides and corresponding polynucleotides
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
CN1315451A (zh) 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人血管形成素类似因子45和编码这种多肽的多核苷酸
AU2001249929A1 (en) 2000-04-07 2001-10-23 Dana-Farber Cancer Institute Inc. Fdrg proteins and nucleic acid molecules and uses therefor
AU784231B2 (en) 2000-06-23 2006-02-23 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
US6673545B2 (en) * 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
CN1170850C (zh) * 2000-09-19 2004-10-13 上海市肿瘤研究所 人血管生成素样蛋白和编码序列及其用途
US20040249141A1 (en) * 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
CA2442741A1 (en) 2001-03-27 2003-01-16 Human Genome Sciences, Inc. Human secreted proteins
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
CA2450022A1 (en) 2001-06-08 2002-12-19 Sankyo Company, Limited Method of testing drug for treating or preventing diseases such as hyperlipemia
WO2003010205A1 (en) 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
JP2005518782A (ja) 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040038230A1 (en) 2001-11-05 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1539985A4 (en) 2001-11-05 2006-06-28 Curagen Corp THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES, AND METHODS OF USE
CA2464542C (en) * 2001-11-16 2015-01-20 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 angptl3
AU2002359464A1 (en) 2001-11-30 2003-06-17 Genvec, Inc. Angiopioetin related factors
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
CA2499791A1 (en) * 2004-03-30 2005-09-30 F. Hoffmann-La Roche Ag Angptl4/fiaf as marker for ppardelta modulation
ATE456579T1 (de) 2004-07-20 2010-02-15 Genentech Inc Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
NZ552957A (en) * 2004-07-20 2011-06-30 Genentech Inc Compositions and methods of using angiopoietin-like 4 protein
CA2594233C (en) * 2005-01-07 2015-02-24 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 )

Also Published As

Publication number Publication date
CN102641503A (zh) 2012-08-22
NZ552956A (en) 2010-03-26
MX2007000784A (es) 2007-04-09
RU2392966C2 (ru) 2010-06-27
AU2005269716A1 (en) 2006-02-09
BRPI0513534A (pt) 2008-05-06
CN101044164A (zh) 2007-09-26
JP2008507536A (ja) 2008-03-13
EP2172482A1 (en) 2010-04-07
EP1771474B1 (en) 2010-01-27
ZA200701183B (en) 2008-05-28
RU2007106076A (ru) 2008-08-27
SI1771474T1 (sl) 2010-06-30
EP2361931A1 (en) 2011-08-31
DK1771474T3 (da) 2010-05-31
KR20070043010A (ko) 2007-04-24
AU2005269716B2 (en) 2011-01-27
US7740846B2 (en) 2010-06-22
EP1771474A2 (en) 2007-04-11
KR101254815B1 (ko) 2013-09-03
JP2012017331A (ja) 2012-01-26
PT1771474E (pt) 2010-05-03
IL180725A0 (en) 2007-06-03
WO2006014729A3 (en) 2007-01-04
PL1771474T3 (pl) 2010-07-30
CA2574758A1 (en) 2006-02-09
EP2361931B1 (en) 2017-12-06
US20060093607A1 (en) 2006-05-04
AU2011201436A1 (en) 2011-04-21
ATE456579T1 (de) 2010-02-15
US20070026002A1 (en) 2007-02-01
JP4947717B2 (ja) 2012-06-06
ES2339789T3 (es) 2010-05-25
WO2006014729A2 (en) 2006-02-09
CY1109931T1 (el) 2014-09-10
NO20070951L (no) 2007-04-20

Similar Documents

Publication Publication Date Title
DE602005019167D1 (de) Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
ATE538136T1 (de) Antikörper gegen connective tissue growth factor
ATE496636T1 (de) Verwendung von agonisten und antagonisten von interleukin-33 (il-33)
ATE511857T1 (de) Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
DE602004021838D1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
NZ606294A (en) B-cell reduction using cd37-specific and cd20-specific binding molecules
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
ATE526987T1 (de) Dr5-antikörper und deren verwendung
DE60029944D1 (de) Polyamine und ihre therapeutische verwendung
DE602006017071D1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
IL187343A0 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1912674A4 (en) BIS SPECIFIC SINGLE CHAIN FV ANTIBODY MOLECULES AND METHOD OF USE THEREOF
WO2007014123A3 (en) Compositions and methods of treating disease with fgfr fusion proteins
PT1242060E (pt) Tratamento da doenca metastatica
WO2007053622A3 (en) Methods for modulating ppar activity to treat diseases caused by mutations in the cftr gene
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
ATE527998T1 (de) Illudin-analoga als krebsmittel
PT1107795E (pt) Tiomolibdato associado com pelo menos um hidrato de carbono e o seu uso para evitar ou tratar doencas caracterizadas por uma vascularizacao tais como cancro degeneracao macular do tipo humido artrite reumatoide
MX2007013834A (es) Terapias de enfermedades vasculares.
WO2007005502A3 (en) Methods and compositions for treating diseases targeting cdcp1
ATE525400T1 (de) Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie
EP2216043A4 (en) USE OF GSE24.2 INDUCTOR AGENTS FOR DEVELOPING PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH CELL SENESCENCE
MY143393A (en) Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy.

Legal Events

Date Code Title Description
8363 Opposition against the patent